The Lancet Haematology

Clonal haematopoiesis to clonal cytopenias: unravelling disease evolution over time.

Pub Date : 2025-07-17 DOI: 10.1016/s2352-3026(25)00137-1 Kristina Kirschner,Yael Kusne,Catherine Cargo,Mrinal M Patnaik

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.

Pub Date : 2025-07-15 DOI: 10.1016/s2352-3026(25)00163-2 Vania Hungria,Marek Hus,ChengCheng Fu,Vera Zherebtsova,Christopher Ward,P Joy Ho,Damian Mikulski,Ludmila Muronova,Claudio Cerchione,Angely Loubert,Laurine Bunod,Manal M'Hari,Nick Pirooz,Rachel Rogers,Chee Paul Lin,Sumita Roy-Ghanta,Joanna B Opalinska,Molly Purser,Astrid McKeown,Simon McNamara,Hena Baig,Lydia Eccersley,Farrah Pompilus,María-Victoria Mateos,

Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study

Pub Date : 2025-06-27 DOI: 10.1016/s2352-3026(25)00139-5 Prof Shaji K Kumar MD, Prof Simon J Harrison PhD, Prof Michele Cavo MD, Prof Javier de la Rubia MD, Rakesh Popat FRCPath, Prof Cristina Gasparetto MD, Prof Vania Hungria MD, Hans Salwender MD, Prof Kenshi Suzuki MD, Prof Inho Kim MD, Maika Onishi MD, Grace Ku MD, Rajvineeth Pothacamury MD, Muhammad Jalaluddin PhD, Jiewei Zeng PhD, Jeremy A Ross PhD, Edyta Dobkowska MD, Prof Philippe Moreau MD